Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02472275 · ClinicalTrials.gov registry record · Phase 1
PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer
A Phase 1 study of Stage II Prostate Adenocarcinoma and Stage III Prostate Adenocarcinoma, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
- 3
- Study locations
NCT02472275 is a Phase 1 study of Stage II Prostate Adenocarcinoma and Stage III Prostate Adenocarcinoma that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 8 participants. The trial reports 3 study locations across 1 state.
The verdict
NCT02472275, a Phase 1 study of Stage II Prostate Adenocarcinoma and Stage III Prostate Adenocarcinoma, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of multitargeted tyrosine kinase inhibitor PLX3397 (PLX3397) when given together with radiation therapy and antihormone therapy in treating patients with prostate cancer that is at intermediate or high risk of spreading. Multitargeted tyrosine kinase inhibitor PLX3397 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth, and may also help the radiation therapy work better. Radiation therapy uses high-energy x-rays to kill tumor cells. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin acetate, or degarelix, may lessen the amount of androgens made by the body. Giving multitargeted tyrosine kinase inhibitor PLX3397 with radiation therapy and antihormone therapy may be a better treatment for prostate cancer.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- RADIATION Radiation Therapy
- DRUG Antiandrogen Therapy
- DRUG Multitargeted Tyrosine Kinase Inhibitor PLX3397
Study Locations (3)
Michigan
- Wayne State University/Karmanos Cancer Institute - Detroit
- Karmanos Cancer Institute at McLaren Northern Michigan - Petoskey Radiation Oncology - Petoskey
- Karmanos Cancer Institute at McLaren Northern Michigan- Petoskey Medical Oncology - Petoskey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-06 |
| Est. Completion | 2019-08-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02472275
The ClinicalTrials.gov registry entry for NCT02472275 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage II Prostate Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02472275 reports 3 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT02472275 about?
NCT02472275 is a clinical study titled "PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer". This phase I trial studies the side effects and best dose of multitargeted tyrosine kinase inhibitor PLX3397 (PLX3397) when given together with radiation therapy and antihormone therapy in treating patients with prostate cancer that is at intermediate or high risk of spreading. Multitargeted tyrosin...
What is the current status of trial NCT02472275?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-06. Estimated completion is 2019-08-05.
What conditions does trial NCT02472275 study?
This clinical trial studies the following conditions: Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma.
What interventions are being tested in trial NCT02472275?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Radiation Therapy (RADIATION), Antiandrogen Therapy (DRUG), Multitargeted Tyrosine Kinase Inhibitor PLX3397 (DRUG).
Who is sponsoring clinical trial NCT02472275?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02472275 being conducted?
This trial has 3 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage II Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Stage II Prostate Adenocarcinoma
All registered trials for this condition
Stage III Prostate Adenocarcinoma
All registered trials for this condition
Michigan
All trials with a study site in Michigan
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.